City Therapeutics (NASDAQ:CTY) Coverage Initiated by Analysts at Jefferies Financial Group

Posted by Don Miller on Nov 10th, 2026

Research analysts at Jefferies Financial Group initiated coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $32.00 price target on the stock. Jefferies Financial Group‘s target price points to a potential upside of 71.40% from the stock’s previous close.

Several other brokerages also recently weighed in on CTY. Oppenheimer assumed coverage on shares of City Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $46.00 target price on the stock. Wall Street Zen raised shares of City Therapeutics to a “hold” rating in a report on Saturday, October 24th. Three research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $37.33.

View Our Latest Research Report on City Therapeutics

City Therapeutics Price Performance

NASDAQ:CTY opened at $18.67 on Tuesday. City Therapeutics has a 1-year low of $15.81 and a 1-year high of $23.88.

Insiders Place Their Bets

In related news, Director Robert Nelsen acquired 170,000 shares of the firm’s stock in a transaction that occurred on Monday, October 19th. The shares were purchased at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the acquisition, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of City Therapeutics stock in a transaction dated Monday, October 19th. The shares were bought at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the transaction, the insider owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The SEC filing for this purchase provides additional information.